Expression of Tryptophan 2,3-Dioxygenase and Production of Kynurenine Pathway Metabolites in Triple Transgenic Mice and Human Alzheimer's Disease Brain

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Wu, Wei ^a   Nicolazzo, Joseph A ^b   Wen, Li ^c   Chung, Roger ^d   Stankovic, Roger ^c   Bao, Shisan S ^c   Lim, Chai K ^a,e   Brew, Bruce J ^f,g   Cullen, Karen M ^c   Guillemin, Gilles J ^a,e  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d UNIVERSITY OF TASMANIA   (Australia)

^e MACQUARIE UNIVERSITY   (Australia)

^f St Vincent's Centre for Applied Medical Research   (Australia)

^g ST VINCENT S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EXCITOTOXIN; INDOLEAMINE 2,3 DIOXYGENASE; KYNURENIC ACID; KYNURENINE; MESSENGER RNA; PICOLINIC ACID; QUINOLINIC ACID; TRYPTOPHAN; TRYPTOPHAN 2,3 DIOXYGENASE;

AGED; ALZHEIMER DISEASE; AMINO ACID ANALYSIS; AMINO ACID SYNTHESIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME LOCALIZATION; ENZYME METABOLISM; GENE EXPRESSION; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; METABOLITE; MOLECULAR PATHOLOGY; MOUSE; NEUROPATHOLOGY; NONHUMAN; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TRANSGENIC MOUSE;

3-HYDROXYANTHRANILATE 3,4-DIOXYGENASE; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANIMALS; CA1 REGION, HIPPOCAMPAL; CA3 REGION, HIPPOCAMPAL; CARBOXY-LYASES; CASE-CONTROL STUDIES; CEREBELLUM; CEREBRAL CORTEX; GENE EXPRESSION; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; KYNURENINE; METABOLIC NETWORKS AND PATHWAYS; MICE; MICE, 129 STRAIN; MICE, INBRED C57BL; MICE, TRANSGENIC; MIDDLE AGED; ORGAN SPECIFICITY; PENTOSYLTRANSFERASES; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRYPTOPHAN; TRYPTOPHAN OXYGENASE;

MUS; MUS MUSCULUS;

EID: 84876449074     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0059749     Document Type: Article

References (50)

1. Stone TW, Perkins MN, (1981) Quinolinic acid: a potent endogenous excitant at amino acid receptors in CNS. Eur J Pharmacol 72: 411-412.
2. Guillemin GJ, (2012) Quinolinic acid, the inescapable neurotoxin. FEBS J.
3. Dale WE, Dang Y, Brown OR, (2000) Tryptophan metabolism through the kynurenine pathway in rat brain and liver slices. Free Radic Biol Med 29: 191-198.
4. Shimizu T, Nomiyama S, Hirata F, Hayaishi O, (1978) Indoleamine 2,3-dioxygenase: purification and some properties. J Biol Chem 253: 4700-4706.
5. Takikawa O, Kuroiwa T, Yamazaki F, Kido R, (1988) Mechanism of interferon-g action. Characterization of indoleamine 2,3-dioxygenase in cultured human cells induced by interferon-g and evaluation of the enzyme mediated tryptophan degradation in its anticellular activity. J Biol Chem 263: 2041-2048.
6. Macchiarulo A, Camaioni E, Nuti R, Pellicciari R, (2009) Highlights at the gate of tryptophan catabolism: a review on the mechanisms of activation and regulation of indoleamine 2,3-dioxygenase (IDO), a novel target in cancer disease. Amino Acids 37: 219-229.
7. Mellor AL, Chandler P, Lee GK, Johnson T, Keskin DB, et al. (2002) Indoleamine 2,3-dioxygenase, immunosuppression and pregnancy. J Reprod Immunol 57: 143-150.
8. Miller CL, Llenos IC, Dulay JR, Barillo MM, Yolken RH, et al. (2004) Expression of the kynurenine pathway enzyme tryptophan 2,3-dioxygenase is increased in the frontal cortex of individuals with schizophrenia. Neurobiol Dis 15: 618-629.
9. Rubin RT, (1967) Adrenal cortical activity changes in manic-depressive illness. Influence on intermediary metabolism of tryptophan. Arch Gen Psychiatry 17: 671-679.
10. Ishimura Y, Nozaki M, Hayaishi O, (1970) The oxygenated form of L-tryptophan 2,3-dioxygenase as reaction intermediate. The Journal of biological chemistry 245: 3593-3602.
11. Kanai M, Nakamura T, Funakoshi H, (2009) Identification and characterization of novel variants of the tryptophan 2,3-dioxygenase gene: differential regulation in the mouse nervous system during development. Neuroscience research 64: 111-117.
12. Widner B, Leblhuber F, Walli J, Tilz GP, Demel U, et al. (2000) Tryptophan degradation and immune activation in Alzheimer's disease. J Neural Transm 107: 343-353.
13. Guillemin GJ, Williams KR, Smith DG, Smythe GA, Croitoru-Lamoury J, et al. (2003) Quinolinic acid in the pathogenesis of Alzheimer's disease. Adv Exp Med Biol 527: 167-176.
14. Guillemin GJ, Brew BJ, Noonan CE, Takikawa O, Cullen KM, (2005) Indoleamine 2,3 dioxygenase and quinolinic acid immunoreactivity in Alzheimer's disease hippocampus. Neuropathol Appl Neurobiol 31: 395-404.
15. Rahman A, Ting K, Cullen KM, Braidy N, Brew BJ, et al. (2009) The excitotoxin quinolinic acid induces tau phosphorylation in human neurons. PLoS One 4: e6344.
16. Bonda DJ, Mailankot M, Stone JG, Garrett MR, Staniszewska M, et al. (2010) Indoleamine 2,3-dioxygenase and 3-hydroxykynurenine modifications are found in the neuropathology of Alzheimer's disease. Redox Rep 15: 161-168.
17. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, et al. (2003) Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 39: 409-421.
18. Guillemin GJ, Cullen KM, Lim CK, Smythe GA, Garner B, et al. (2007) Characterization of the Kynurenine Pathway in Human Neurons. J Neurosci 27: 12884-12892.
19. Ruddick JP, Evans AK, Nutt DJ, Lightman SL, Rook GA, et al. (2006) Tryptophan metabolism in the central nervous system: medical implications. Expert Rev Mol Med 8: 1-27.
20. Takikawa O, (2005) Biochemical and medical aspects of the indoleamine 2,3-dioxygenase-initiated l-tryptophan metabolism. Biochem Biophys Res Commun 338: 12-19.
21. Munn DH, Shafizadeh E, Attwood JT, Bondarev I, Pashine A, et al. (1999) Inhibition of T cell proliferation by macrophage tryptophan catabolism. J Exp Med 189: 1363-1372.
22. Kanai M, Nakamura T, Funakoshi H, (2009) Identification and characterization of novel variants of the tryptophan 2,3-dioxygenase gene: differential regulation in the mouse nervous system during development. Neurosci Res 64: 111-117.
23. Kanai M, Funakoshi H, Takahashi H, Hayakawa T, Mizuno S, et al. (2009) Tryptophan 2,3-dioxygenase is a key modulator of physiological neurogenesis and anxiety-related behavior in mice. Mol Brain 2: 8.
24. Ohira K, Hagihara H, Toyama K, Takao K, Kanai M, et al. (2010) Expression of tryptophan 2,3-dioxygenase in mature granule cells of the adult mouse dentate gyrus. Mol Brain 3: 26.
25. Miller CL, Llenos IC, Dulay JR, Weis S, (2006) Upregulation of the initiating step of the kynurenine pathway in postmortem anterior cingulate cortex from individuals with schizophrenia and bipolar disorder. Brain Res 1073-1074: 25-37.
26. Henry CJ, Huang Y, Wynne AM, Godbout JP, (2009) Peripheral lipopolysaccharide (LPS) challenge promotes microglial hyperactivity in aged mice that is associated with exaggerated induction of both pro-inflammatory IL-1beta and anti-inflammatory IL-10 cytokines. Brain Behav Immun 23: 309-317.
27. Melillo G, Bosco MC, Musso T, Varesio L, (1996) Immunobiology of picolinic acid. Adv Exp Med Biol 398: 135-141.
28. Jhamandas K, Boegman RJ, Beninger RJ, Bialik M, (1990) Quinolinate-induced cortical cholinergic damage: modulation by tryptophan metabolites. Brain Res 529: 185-191.
29. Vrooman L, Jhamandas K, Boegman RJ, Beninger RJ, (1993) Picolinic acid modulates kainic acid-evoked glutamate release from the striatum in vitro. Brain Res 627: 193-198.
30. Bosco MC, Rapisarda A, Massazza S, Melillo G, Young H, et al. (2000) The tryptophan catabolite picolinic acid selectively induces the chemokines macrophage inflammatory protein-1alpha and-1beta in macrophages. J Immunol 164: 3283-3291.
31. Braidy N, Guillemin GJ, Grant R, (2011) Effects of Kynurenine Pathway Inhibition on NAD Metabolism and Cell Viability in Human Primary Astrocytes and Neurons. Int J Tryptophan Res 4: 29-37.
32. Alberati-Giani D, Ricciardi-Castagnoli P, Kohler C, Cesura AM, (1996) Regulation of the kynurenine metabolic pathway by interferon-gamma in murine cloned macrophages and microglial cells. J Neurochem 66: 996-1004.
33. Roy EJ, Takikawa O, Kranz DM, Brown AR, Thomas DL, (2005) Neuronal localization of indoleamine 2,3-dioxygenase in mice. Neurosci Lett 387: 95-99.
34. Guillemin GJ, Smythe G, Takikawa O, Brew BJ, (2005) Expression of indoleamine 2,3-dioxygenase and production of quinolinic acid by human microglia, astrocytes, and neurons. Glia 49: 15-23.
35. Lim CK, Smythe GA, Stocker R, Brew BJ, Guillemin GJ, (2007) Characterization of the kynurenine pathway in human oligodendrocytes. International Congress Series 1304.
36. Espey MG, Chernyshev ON, Reinhard JJ, Namboodiri MA, Colton CA, (1997) Activated human microglia produce the excitotoxin quinolinic acid. Neuroreport 8: 431-434.
37. Guillemin GJ, Smith DG, Smythe GA, Armati PJ, Brew BJ, (2003) Expression of the kynurenine pathway enzymes in human microglia and macrophages. Adv Exp Med Biol 527: 105-112.
38. Guillemin GJ, Kerr SJ, Smythe GA, Smith DG, Kapoor V, et al. (2001) Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection. J Neurochem 78: 1-13.
39. Fukuoka S, Ishiguro K, Tanabe A, Egashira Y, Sanada H, et al. (2003) Identification and expression of alpha cDNA encoding human 2-amino-3-carboxymuconate-6-semialdehyde decarboxylase (ACMSD): a key enzyme for the tryptophan-niacine pathway and quinolinate hypothesis. Adv Exp Med Biol 527: 443-453.
40. Guillemin GJ, Brew BJ, Noonan CE, Knight TG, Smythe GA, et al. (2007) Mass spectrometric detection of quinolinic acid in microdissected Alzheimer's disease plaques. In: Takai K, editor. International Congress Series. pp. 404-408.
41. Guillemin GJ, Smith DG, Williams K, Smythe GA, Dormont D, et al. (2001) β amyloid peptide 1-42 induces human macrophages to produce the neurotoxin quinolinic acid. J Neuroimmunol 118 (112. A): 336.
42. Yamada A, Akimoto H, Kagawa S, Guillemin GJ, Takikawa O, (2009) Proinflammatory cytokine interferon-gamma increases induction of indoleamine 2,3-dioxygenase in monocytic cells primed with amyloid beta peptide 1-42: implications for the pathogenesis of Alzheimer's disease. J Neurochem 110: 791-800.
43. Heyes MP, Chen CY, Major EO, Saito K, (1997) Different kynurenine pathway enzymes limit quinolinic acid formation by various human cell types. Biochemical Journal 326: 351-356.
44. Lapin IP, Oxenkrug GF, (1969) Intensification of the central serotoninergic processes as a possible determinant of the thymoleptic effect. Lancet 1: 132-136.
45. Huang CW, Lui CC, Chang WN, Lu CH, Wang YL, et al. (2009) Elevated basal cortisol level predicts lower hippocampal volume and cognitive decline in Alzheimer's disease. J Clin Neurosci 16: 1283-1286.
46. Oxenkrug GF, (2010) Interferon-gamma-inducible kynurenines/pteridines inflammation cascade: implications for aging and aging-associated psychiatric and medical disorders. J Neural Transm.
47. McGeer PL, McGeer EG, (2002) Local neuroinflammation and the progression of Alzheimer's disease. J Neurovirol 8: 529-538.
48. Zwilling D, Huang SY, Sathyasaikumar KV, Notarangelo FM, Guidetti P, et al. (2011) Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration. Cell 145: 863-874.
49. Pilotte L, Larrieu P, Stroobant V, Colau D, Dolusic E, et al. (2012) Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase. Proc Natl Acad Sci U S A 109: 2497-2502.
50. Lob S, Konigsrainer A, Schafer R, Rammensee HG, Opelz G, et al. (2008) Levo- but not dextro-1-methyl tryptophan abrogates the IDO activity of human dendritic cells. Blood 111: 2152-2154.